Excitation-Dependent Theranostic Nanosheet for Cancer Treatment

Adv Healthc Mater. 2018 May;7(10):e1701123. doi: 10.1002/adhm.201701123. Epub 2018 Feb 12.

Abstract

In this work, a novel ruthenium complex loaded monolayer layered double hydroxide (LDH) (denoted as Ru(C-bpy)2 /mLDH) as supramolecular nanosensor is synthesized, which is greatly exclusive to the hypoxic tumor microenvironment. The Ru(C-bpy)2 /mLDH ultrathin sheet displays not only enhanced luminescence lifetime compared to the parent Ru(C-bpy)2 alone, but also improved oxygen responsibility under an excitation of 488 or 800 nm. Moreover, the Ru(C-bpy)2 /mLDH is possessed of two-photon fluorescence imaging ability under the 800 nm irradiation. In addition, the Ru(C-bpy)2 /mLDH can generate singlet oxygen with a high yield (φ∆ ) of 0.28 under the 520 nm irradiation, while the φ∆ of Ru(C-bpy)2 is 0.19. Therefore, the Ru(C-bpy)2 /mLDH can be applied as a supramolecular theranostic agent with light-switchable cancer imaging and photodynamic therapy properties.

Keywords: excitation-triggered theranosis; fluorescence imaging; hypoxia responsive; nanosheets; photodynamic therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Diagnostic Imaging
  • HeLa Cells
  • Humans
  • Luminescent Measurements
  • Mice
  • Mice, Nude
  • Nanostructures* / chemistry
  • Nanostructures* / therapeutic use
  • Neoplasms, Experimental* / drug therapy
  • Neoplasms, Experimental* / metabolism
  • Neoplasms, Experimental* / pathology
  • Photochemotherapy*
  • Ruthenium Compounds* / chemical synthesis
  • Ruthenium Compounds* / chemistry
  • Ruthenium Compounds* / pharmacology
  • Theranostic Nanomedicine* / methods
  • Tumor Hypoxia*
  • Tumor Microenvironment*
  • Xenograft Model Antitumor Assays

Substances

  • Ruthenium Compounds
  • ruthenium chloride